Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.45 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.45 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.45 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540059 | 0.86 | L3MBTL1 (0.49) | L3MBTL1KMT2AMEN1LPAR1LPAR5 | |
| SCHEMBL6552605 | 0.85 | LPAR1 (0.62) | L3MBTL1KMT2AMEN1LPAR1ACHE | |
| SCHEMBL6539665 | 0.85 | LPAR1 (0.57) | L3MBTL1KMT2AMEN1LPAR1LPAR5 | |
| SCHEMBL6540146 | 0.81 | LPAR1 (0.52) | L3MBTL1KMT2AMEN1LPAR1ACHE | |
| SCHEMBL6541428 | 0.81 | L3MBTL1 (0.58) | L3MBTL1LPAR1GAA | |
| SCHEMBL6540922 | 0.80 | L3MBTL1 (0.48) | L3MBTL1KMT2AMEN1LPAR1BCHE | |
| SCHEMBL6540825 | 0.80 | OPRK1 (0.50) | L3MBTL1KMT2AMEN1LPAR1LPAR5 | |
| SCHEMBL7228409 | 0.75 | MEN1 (0.61) | L3MBTL1KMT2AMEN1 | |
| SCHEMBL6540023 | 0.74 | L3MBTL1 (0.51) | L3MBTL1KMT2AMEN1LPAR1LPAR5 | |
| SCHEMBL6541405 | 0.74 | LPAR1 (0.54) | L3MBTL1KMT2AMEN1LPAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | L3MBTL1 2987/4885KMT2A 432/4885MEN1 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.